The RESPOND-CRT trial successfully met its primary endpoint demonstrating that automatic AV and VV optimization using the SonR contractility sensor is safe and as effective as Echo- guided AV and VV optimization.
75% of clinical responders in the SonR group versus 70% in the control group1 (p<0.001)
The SonRtip lead was proven to be safe, with only 1% of patients reporting lead dislodgement and 0.1% of patients reporting lead fracture.
The RESPOND-CRT landmark trial revealed that sensor-based CRT optimization with SonR is associated with a 35% reduced risk in heart failure hospitalization.
1. Brugada, J., P. P. Delnoy, J. Brachmann, D. Reynolds, L. Padeletti, G. Noelker, C. Kantipudi, et al. 2016. “Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial.” European Heart Journal 38 (10): 730-738. doi:10.1093/eurheartj/ehw526.
This site is intended for healthcare professionals outside the United States of America. By continuing to use this site you are confirming that that you are a healthcare professional based outside the USA.